- Title: Randomized Clinical Trial of ICECaP (Individualized Coordination and Empowerment for Care Partners 1 2 of Persons with Dementia): Primary Mental Health and Burden Outcomes 3
- 4 Short Title: ICECaP Pilot RCT: Mental Health and Burden Outcomes

Authors: Virginia T. Gallagher, PhD<sup>\*1</sup>, Anna Arp, BS<sup>2</sup>, Ryan Thompson, PhD<sup>1</sup>, Agustina Rossetti, PhD<sup>1</sup>, James Patrie, MS<sup>3</sup>, Shannon E Reilly, PhD<sup>1</sup>, Carol A. Manning, PhD<sup>1</sup> 7

- \*Corresponding author, vgallagher@virginia.edu, PO BOX 801018, Charlottesville, Virginia, 22903 9
- <sup>1</sup>Department of Neurology, University of Virginia, Charlottesville, Virginia 10
- <sup>2</sup>Brain Institute, University of Virginia, Charlottesville, Virginia 11
- <sup>3</sup>Department of Biostatistics, University of Virginia, Charlottesville, Virginia 12
- Funding: This work was funded by the Department of Defense (AZ190036); program development and pilot 14 feasibility testing was funded by the Virginia Department for Aging and Rehabilitative Services (45918). 15
- REDCap support at the University of Virginia is supported in part by the National Center for Advancing 16
- Translational Sciences of the National Institutes of Health under Award # UL1TR003015. 17
- 18 19 Conflicts of interest: None.
- 20

5 6

8

13

Registration: ClinicalTrials.gov NCT04495686 An Innovative Support Care Model for Dementia and Traumatic 21 Brain Injury 22

- 23
- 24 The full trial protocol can be made available upon request.

25 Abstract: Efficacy of the Individualized Coordination and Empowerment for Care Partners of Persons with Dementia (ICECaP), an intervention that involves one-on-one individualized support from a dementia care 26 coordinator for a dementia care partner, compared to an active control group. At least once monthly contact is 27 made from a dementia care coordinator to the dementia care partner by telephone, video conferencing, email. 28 or in-person support at clinical visits for the person with dementia. In this pilot randomized unblinded control 29 trial of ICECaP, n=61 (n=90 randomized) care partners completed 12-months of the ICECaP intervention and 30 n=69 (n=92 randomized) care partners received routine clinical support (controls) in an outpatient memory care 31 clinic at an academic medical center, from which the participants were recruited (ClinicalTrials.gov: 32 NCT04495686, funded by Department of Defense and Virginia Department for Aging and Rehabilitative 33 Services). Early termination endpoints (death and higher level of care) and trial drop out were comparable 34 35 across groups. Primary efficacy outcomes were evaluated by comparing changes in care partner mental health, burden, and quality of life from baseline to 12-months between ICECaP and controls. Linear-mixed 36 ANCOVA revealed no significant group differences in longitudinal changes on measures of caregiving burden. 37 care partner depression, anxiety, guality of life, or reactions to the behavioral symptoms of the person with 38 dementia. Hypothesized reasons for lack of initial efficacy on primary 12-month outcomes are discussed. 39

## Introduction

40	Introduction
41	There are over 11 million family members and friends providing unpaid care for persons with dementia
42	in the United States. Informal dementia caregiving is valued at \$350 billion and 18.4 billion hours of care per
43	year nationally. <sup>1</sup> Although many dementia care partners experience meaning and fulfillment in the context of
44	their caregiving role, caring for a person with dementia is associated with increased levels of psychosocial
45	stress, depression, and emotional burden. <sup>2–9</sup>
46	Many programs and interventions have been developed to support dementia care partners and improve
47	their mental health, quality of life, and caregiving readiness. Among them, collaborative care coordination has
48	emerged as a promising, individualized intervention to help care partners and their care recipients with
49	dementia navigate complex health systems, financial/insurance systems, and community resources.
50	Additionally, care partners are provided with social and emotional support. <sup>10–13</sup> A team at the University of
51	Virginia, along with its partners, developed an intervention for dementia care partners called ICECaP:
52	Individualized Coordination and Empowerment for Care Partners of Persons with Dementia to support
53	dementia care partners. ICECaP involves individualized elements of care coordination, supportive counseling,
54	psychoeducation, and skills training and is delivered in a hybrid setting – combining an optional initial home
55	visit; ongoing, at least-monthly telehealth interactions via phone, email, and HIPAA-compliant video calls; and
56	accompaniment to clinic visits for the person with dementia.
57	In this article, we report preliminary, primary efficacy outcomes for a pilot, randomized unblinded control
58	trial (RCT) of ICECaP. Please see Gallagher et al. 2024 for program details, the ICECaP protocol, and
59	analytical plan. <sup>14</sup> We evaluate Aim 1 of the ICECaP RCT: determine whether ICECaP improves care partner
60	burden, symptoms of depression, reaction to the behavioral symptoms of dementia, and quality of life. We

hypothesized that after controlling for baseline characteristics, including level of care-recipient functional 61

- 62 dependence, care partners in the ICECaP group would significantly improve from baseline to 12 months (post-
- intervention) on mental health and quality of life measures, whereas controls would not improve. 63
- 64

65

## Methods

66 This study was approved by the University of Virginia Institution Research Board for Health Services 67 Research and registered with clinicaltrials.gov (NCT04495686). All care partners underwent a written informed 68 consent process one-on-one with a trained clinical research coordinator (CRC) prior to initiating study 69 procedures. Consent was documented with the signature of the participant and the CRC. All participants were 70 provided with a signed copy of the consent document.

#### 71 Recruitment

As reported in the published protocol<sup>14</sup> and the feasibility and acceptability data for the ICECaP clinical 72 trial (Thompson et al., currently under review), care partners were recruited from March 1, 2021 to September 73 30, 2022 from the University of Virginia's multidisciplinary Memory and Aging Care Clinic (MACC) when 74 75 accompanying a patient with dementia to a clinical appointment. Care partners were required to be aged  $\geq 18$ 76 years, possess basic spoken and written English skills, have home-based internet access, and self-identify as the primary care partner for a patient diagnosed with mild to moderate dementia living in the community (e.g., 77 not living in a continuing care facility). During the course of the trial, eligibility criteria was expanded to include 78 patient populations being overlooked for recruitment. Changes made included lowering age requirements, and 79 including multiple etiologies of dementia. Using a random permuted block randomization scheme generated by 80 81 the study statistician and implemented by the clinical research coordinator at enrollment, care partners were randomly assigned to 12-months of ICECaP or 12-months of routine clinical care (controls). 82

#### 83 Target sample size

Based on an a priori power analysis, the target sample size was n=140 CPs, (50% ICECaP and 50% control) to achieve at least 0.80 power for detecting a small-to-medium Cohen's *d* effect size (d = 0.3 to 0.5) when comparing baseline to 12-month mean change in the care partner's depression score (Center for Epidemiological Studies Depression Scale–Revised) and when comparing the baseline to 12-month mean change the care partner's burden score (Zarit Burden Interview) between ICECaP and control groups at a significance level of  $\alpha = .05$ .

90

### 91 Sample and Attrition

- As described in Thompson et al. (under review), of the n=169 (control n=87, ICECap n=82) care
- 93 partners recruited into the RCT who completed baseline assessments (out of 182 participants randomized),
- 94 23.08% were withdrawn from the final sample because within 12-months, the person with dementia died (n=9),
- 95 moved to a higher level of care (n=8), or moved out of state (n=1); or the care partner chose to withdraw (n=4),
- 96 was lost to follow-up despite two attempts to contact (n=13), or did not complete 12-month assessments (n=4).
- 97 See Figure 1. The final sample of care partners included n=69 controls and n=61 ICECaP who completed
- 98 baseline and 12-month assessments.
- 99 **Procedures and Intervention**
- 100 Please see Gallagher et al., 2024 for details. Questionnaires listed in Table 1 were completed online by
- 101 both ICECaP and control groups at baseline and 12-months after baseline. Additional questionnaires for
- 102 sample characterization included the Katz Index of Independence in ADLs (Katz Basic ADLs),<sup>15</sup> the Lawton-
- 103 Brody Instrumental ADL Scale (Lawton-Brody Complex ADLs),<sup>16</sup> and the Neuropsychiatric Inventory
- 104 Questionnaire, all completed by the care partner about the person with dementia.<sup>17</sup> All measures were
- 105 collected and stored using REDCap<sup>18</sup>, hosted by the University of Virginia, and were monitored by the clinical
- 106 research coordinator for missing data.

Table 1. ICECaP Randomized Clinical Trial Primary Outcome Measures					
Construct	Self-report Measure	Measure Details			
Care partner burden	Zarit Burden Interview (ZBI) <sup>19</sup>	22-item measure assessing degree of caregiving burden			
Care partner depression	Center for Epidemiologic Studies Depression Scale—Revised (CESD- R) <sup>20</sup>	20-item measure assessing symptoms of depression			
Care partner anxiety	Geriatric Anxiety Inventory (GAI) <sup>21</sup>	20-item measure assessing symptoms of anxiety			
Care partner reaction to behavioral symptoms of dementia	Revised Memory and Behavior Problem Checklist (RMBPC) <sup>22</sup>	24-item measure assessing care partner-reported problematic behaviors in the person with dementia and the care partner's reaction to the behaviors			
Care partner quality of life	WHO (Five) Well-Being Index (WHO-5) <sup>23</sup>	5-item measure assessing dimensions of psychological well-being			

107

108 Intervention. After baseline questionnaires were completed, a trained dementia care coordinator (referred to

109 going forward as care coordinator) called or e-mailed care partners in the ICECap group to schedule the initial

- 110 contact. Care coordinators contacted the care partner at least once per month via email, telehealth
- 111 phone/video, or an in-person meeting for at least 15 minutes. During these contacts, care coordinators

- provided supportive counseling and related services based on the needs of the care partner (e.g., behavioral
   management, safety strategies, case management, healthcare referrals, psychoeducation). Care partners
   were encouraged to contact care coordinators as needed. After the initial contact, care coordinators were also
- required to attend regular follow-up appointments in the Memory and Aging Care Clinic with the care partner
- and their associated person with dementia. These follow-up appointments typically occur every 6 to 12 months.
- 117 <u>Control Group.</u> Care partners in the control group received standard care as provided by the MACC (e.g.,
- follow-up appointments every 6 to 12 months). They filled out the same questionnaires at baseline and 12
- 119 months as the care partners in the ICECaP intervention group.

#### 120 Statistical Analysis

121 <u>Data summarization</u>. Descriptive categorical data were summarized by frequencies (n) and relative frequencies

- 122 (%), and descriptive continuous scaled data were summarized by the either the mean and standard deviation
- (SD) or the median and interquartile range of the distribution.
- <u>Baseline analysis</u>. Although randomization imbalance with respect to the baseline demographic and caregiving
   characteristics of the ICECaP and control groups would expect to be rare, sensitivity analyses were conducted
- to assess for such imbalances. Statistical comparisons of distribution means were conducted via the Welch
- 127 two-sample t-test, while statistical comparisons of distribution medians were conducted by the Wilcoxon two-
- sample Rank Sum test. Statistical comparisons of the relative frequencies of each characteristic were
- 129 conducted by the Pearson two-sample exact test.
- 130 Efficacy analyses. Pre- to post-intervention 12-month changes in care partner burden (ZBI total score),
- depression (CESD-R total score), anxiety (GAI total score), reaction to dementia symptoms (RMBPC Reaction
- score) and quality of life (WHO-5 score) were the focus of the ICECaP trial efficacy analyses. Each efficacy
- analysis was conducted using a two-step analytical approach. In step 1, a linear mixed ANOVA model was
- 134 used to estimate under the relaxed heterogenous, versus homogenous equal variance assumption, the
- 135 intervention-specific mean pre- to post-intervention 12-month efficacy outcome change. A linear mixed model-
- derived one-sample t-test was then used to test the null hypothesis that the mean pre- to post-intervention 12-
- month efficacy outcome change is equal to zero (versus the alternative: not equal to zero). A two-sided  $\alpha$ =0.05
- 138 significance level was used. In step 2, a linear mixed ANCOVA model was used to test the null hypothesis that

- the mean pre- to post-intervention 12-month efficacy outcome change is equal for the two groups after
- 140 accounting for between-group disparities in the relevant baseline care partner outcome, in baseline Katz Basic
- ADLs, and in baseline Lawton-Brody Complex ADLs (versus the alternative: the mean pre- to post-intervention
- 142 12-month adjusted efficacy outcome change is not equal). A linear model adjusted contrasts of means was
- used to test the null hypothesis, and a two-sided  $\alpha$ =0.05 significance level was used.
- 144

#### Results

#### 145 **Baseline Results**

- 146 There were no significant group differences on baseline demographic and caregiving characteristics between
- the ICECaP and control groups (ps > .05 across comparisons; see Table 2).

Table 2. Care Partner Demographic and Caregiving Characteristics						
	ICECaP	Controls				
	(n=61)	(n=69)	P-value			
Years of age [M(SD)]	64.8 (12.3)	64.9 (11.6)	0.968			
Gender (women)	42 (68.9%)	52 (75.4%)	0.438			
Race/Ethnicity						
Non-Hispanic White	57 (93.4%)	60 (87.0%)				
Non-Hispanic Black/African American	3 (4.9%)	4 (5.8%)	0 700			
Hispanic/Latino	1 (1.6%)	3 (4.3%)	0.790			
Non-Hispanic American Indian	0 (0.0%)	1 (1.4%)				
Highest level of education completed						
High school diploma or GED	5 (8.2%)	5 (7.2%)				
Some college	10 (16.4%)	8 (11.6%)				
Associate's degree	4 (6.6%)	8 (11.6%)	0.010			
Bachelor's degree	27 (44.3%)	25 (36.2%)	0.010			
Master's degree	11 (18.0%)	15 (21.7%)				
Doctoral degree	4 (6.6%)	6 (8.7%)				
Employment status*						
Retired	24 (39.3%)	39 (56.5%)				
Full-time	15 (24.6%)	15 (21.7%)	0.051			
Part-time	9 (14.8%)	2 (2.9%)	0.051			
Unemployed	2 (3.3%)	3 (4.3%)				
Monthly income						
\$1-\$4,999	24 (39.3%)	19 (27.5%)				
\$5,000-\$9,999	13 (21.3%)	18 (26.1%)	0.255			
\$10,000-\$14,999	4 (6.6%)	5 (7.2%)	0.255			
\$15,000-\$24,999	4 (6.6%)	11 (15.9%)				
Relationship to PWD						
Spouse/Partner	44 (72.1%)	49 (71.0%)	1 000			
Adult Child	14 (23.0%)	16 (23.2%)	1.000			
Co-dwelling with PWD	47 (77.0%)	54 (78.3%)	0.688			
CP hours/month supporting basic ADLs for PWD	3.8 [0, 30.0]	0 [0, 48.7]	0.976			
[MD [IQR]]						
CP hours/month supporting complex ADLs for	30.0 [7.1, 9.0]	60.0 [19.0, 120.0]	0.067			
PWD [MD [IRQ]]			0.007			
Katz Index of Independence in (Basic) ADLs for	7.3 (0.9)	7.6 (1.1)	0.109			
PWD [M(SD)]						

Table 2. Care Partner Demographic and Caregiving Characteristics				
	ICECaP (n=61)	Controls (n=69)	P-value	
Lawton-Brody Instrumental (Complex) ADL Scale for PWD [M(SD)]	3.9 (2.2)	3.7 (2.1)	0.659	
Neuropsychiatric Inventory Questionnaire- PWD Severity Score [M(SD)] <sup>17</sup>	6.1 (5.1)	5.7 (4.7)	0.630	
<i>Note</i> . Data presented as <i>n</i> (% of group) unless otherwise noted. ADLs = activities of daily living; CP = care partner; M(SD) = Mean (Standard Deviation); MD [IQR] = Median [Interquartile Range] PWD = person with dementia.				

148

149 There were no significant differences in baseline scores on any primary outcome measures between groups

150 (see Table 3). Within both groups at baseline, caregiver burden fell in the mild to moderate range; mean

depression scores and anxiety scores fell below the threshold for at-risk clinical depression and anxiety,

respectively; mean reaction to behavioral symptoms of dementia fell between "a little" to "moderately" bothered

by the person with dementia's symptoms. There is no established cut-off for the WHO-5 quality of life score.

Table 3. ICECaP Intervention Primary 12-Month Efficacy Results									
	ICECaP (n=61)				Controls (n=69)				ANCOVA Models
Construct	Baseline Mean (SD)	12-Month Mean (SD)	Mean ∆ [95% Cl]	P-value <sup>1</sup>	Baseline Mean (SD)	12-Month Mean (SD)	Mean ∆ [95% CI]	P-value <sup>2</sup>	P-value <sup>3</sup>
Burden	17.30 (7.84)	18.38 (7.82)	1.25 [-0.56, 3.06]	0.173	17.74 (7.96)	18.74 (7.58)	1.00 [-0.44, 2.44]	0.170	0.955
Depression	9.11 (11.06)	10.43 (10.83)	1.33 [-1.55, 4.21]	0.358	11.22 (11.15)	13.14 (13.68)	1.93 [-0.10, 3.96]	0.062	0.563
Anxiety	4.46 (4.70)	4.31 (4.61)	-0.15 [-1.28, 0.99]	0.796	4.62 (4.81)	5.01 (4.64)	0.39 [-0.31, 1.10]	0.272	0.396
Reaction to dementia sx	1.31 (0.69)	1.25 (0.71)	-0.05 [-0.26, 0.16]	0.621	1.34 (0.65)	1.40 (0.65)	0.06 [-0.09, 0.21]	0.441	0.204
Quality of life	14.21 (5.13)	13.95 (5.31)	-0.40 [-1.62, 0.82]	0.515	13.77 (4.71)	13.41 (5.20)	-0.38 [-1.41, 0.65]	0.468	0.954

Constructs were measured using the following questionnaires: Burden = ZBI-SF; Depression = CESD-R; Anxiety = GAI; Reaction to Dementia sx (Symptoms) = RMBPC Reaction score; Quality of Life = WHO-5

P-values<sup>1-2</sup> were derived from linear mixed model one-sample t-test for testing the null hypothesis that the mean change ( $\Delta$ ) from baseline to 12months is equal to zero. P-values<sup>3</sup> were derived from the linear mixed ANCOVA model two-sample test for comparing the mean change from baseline to 12-months ( $\Delta$ ) between ICECaP and control groups after adjusting for baseline Katz Index of Independence in (Basic) ADLs and Lawton-Brody Instrumental (Complex) ADL Scale for PWD. Analysis was by originally assigned groups.

#### 157 Longitudinal Results

158 There were no significant differences in baseline to 12-month change on primary outcome

159 measures between ICECaP and controls (see Table 3). Results were consistent when the Katz

160 Basic ADLs and Lawton-Brody Complex ADLs were included as covariates in analyses.

161 Harms

162 There were no harms associated with the intervention. Inherent harms of providing care for a

163 person with dementia include possible depressive episodes.

164

#### Discussion

165 This paper presents the preliminary, 12-month efficacy results of a pilot RCT of the ICECaP intervention for care partners of persons with dementia. On average, the 12-month 166 intervention did not appear to significantly change care partners' self-reported levels of burden, 167 depression, anxiety, quality of life, or reaction to behavioral symptoms in the person with 168 169 dementia. There were no significant differences between the ICECaP intervention group and the 170 control group in key outcomes at baseline, 12-months, or in change from baseline to 12-months. There are several possible explanations why there were no significant mental health, 171 172 burden, or quality of life benefits detected in this 12-month RCT of ICECaP. First, this cohort of 173 dementia care partners did not indicate experiencing elevated mental health distress, severe 174 caregiving burden, or poor quality of life at baseline according to self-report measures. This is consistent with the relatively high socioeconomic status of this sample, who are majority non-175 176 Hispanic White and well educated, rendering them less vulnerable to adverse impacts of 177 caregiving. Therefore, a floor effect may be present in which care partners' self-report measure scores did not have ample room to allow for change in a positive (i.e., improved) direction. 178 Additionally, the relatively high socioeconomic status of the current sample limits generalizability 179 180 of these findings to caregivers from more diverse socioeconomic backgrounds. In sum, future 181 efficacy testing of ICECaP should have more restrictive inclusion criteria to include only care

partners who have elevated levels of the target factor (e.g., burden, depression, and/or anxiety)
 and greater consideration of diverse socioeconomic statuses.

Additionally, no differential group-by-time effects may have been detected in this RCT 184 due to the nature of the control group in this study. Specifically, all care partners included in 185 186 both the intervention and control group received follow-up care in the UVA Memory and Aging Care Clinic (MACC). Follow-up care in MACC typically involves a one-hour appointment for the 187 person with dementia and their care partner(s) one to two times per year with a multidisciplinary 188 189 team of neuropsychologists, neuropsychology postdoctoral fellows, a nurse practitioner, a 190 pharmacist, an occupational therapist, and a speech-language pathologist, among other 191 specialties. While these appointments are scheduled for the person with dementia, the 192 accompanying care partner receives information about pharmacological and nonpharmacological behavioral management strategies; long-term care planning support; dementia 193 194 psychoeducation; psychotherapy and support group options for care partners; information 195 regarding adult day, continuing care, and respite facilities; and other local resources. Further, care partners are often provided emotional support, validation, and encouragement; at times, 196 197 the care partner and the person with dementia are separated during the appointment so a care 198 partner can receive one-on-one validation and support (e.g., while the person with dementia is 199 completing brief testing to inform treatment recommendations). Although once to twice yearly 200 support in the multidisciplinary clinic is a lower frequency and intensity of support relative to the 201 monthly support care partners receive in ICECaP, it is possible that there is too much overlap in 202 support that was provided to both the ICECaP group and the control group to detect a signal. In 203 the future, it may be more appropriate to restrict the control group to care partners in the 204 community who are on the waitlist for specialty care services.

Another possible reason for the lack of differential changes on outcome measures between the ICECaP and control groups over time could be the variability in "dosage" of the intervention in the ICECaP group. As Thompson et al. (manuscript currently under review)

208 reported, the number of contacts between dementia care coordinators and care partners in the 209 ICECaP group was significantly variable. Care partners and care coordinators had an average 210 of 2.2 contacts per month, averaged across 12-months within the ICECaP group; however, the number of contacts in a month ranged from 0 to 15 contacts. Further, while all care partners had 211 212 a least one contact with a care coordinator during at least 11 of the 12 months of ICECaP, 213 25.6% of care partners had one month with 0 contacts with the care coordinator. In sum, it is possible that the intervention is efficacious for improving mental health, burden, and quality of 214 215 life for those who are highly engaged in the program (e.g., > monthly contact with a care 216 coordinator; care partner utilizes resources effectively by following through on care coordinator 217 recommendations) but that engagement was too variable within the intervention group to detect 218 improvement on outcome measures relative to the control group. Future analyses will focus on 219 the extent to which engagement metrics impact efficacy of the intervention. 220 While the ICECaP pilot RCT did not demonstrate significant impacts of ICECaP on care

partner mental health and caregiving burden, secondary analyses have revealed promising effects on other aspects of caregiver wellbeing (manuscript in preparation). Specifically, ICECaP appears to improve care partners' preparedness for caregiving, which has downstream correlates with improvement in mental health measures. Collectively, the results from this manuscript and the forthcoming manuscript on ICECaP primary and secondary outcomes will provide important considerations for further refinement and testing of the ICECaP intervention.

227

# 228 Acknowledgements

229 None.

230

232		References
233 234	1.	Alzheimer's Association. 2024 Alzheimer's Disease Facts and Figures. n.d.
235 236 237	2.	Mahoney R, Regan C, Katona C, et al. Anxiety and depression in family caregivers of people with Alzheimer disease: the LASER-AD study. Am J Geriatr Psychiatry 2005;13(9):795–801; doi: 10.1176/appi.ajgp.13.9.795.
238 239 240	3.	Abdollahpour I, Nedjat S, Salimi Y, et al. Which variable is the strongest adjusted predictor of quality of life in caregivers of patients with dementia? Psychogeriatrics 2015;15(1):51–57; doi: 10.1111/psyg.12094.
241 242 243	4.	Huang S-S. Depression among caregivers of patients with dementia: Associative factors and management approaches. World J Psychiatry 2022;12(1):59–76; doi: 10.5498/wjp.v12.i1.59.
244 245 246	5.	Sallim AB, Sayampanathan AA, Cuttilan A, et al. Prevalence of Mental Health Disorders Among Caregivers of Patients With Alzheimer Disease. J Am Med Dir Assoc 2015;16(12):1034–1041; doi: 10.1016/j.jamda.2015.09.007.
247 248	6.	Chiao C-Y, Wu H-S, Hsiao C-Y. Caregiver burden for informal caregivers of patients with dementia: A systematic review. Int Nurs Rev 2015;62(3):340–350; doi: 10.1111/inr.12194.
249 250 251	7.	Zarit SH, Savla J. Caregivers and Stress. In: Stress: Concepts, Cognition, Emotion, and Behavior. (Fink G. ed) Academic Press: San Diego; 2016; pp. 339–344; doi: 10.1016/B978-0-12-800951-2.00042-X.
252 253 254	8.	Collins RN, Kishita N. Prevalence of depression and burden among informal care-givers of people with dementia: a meta-analysis. Ageing & Society 2020;40(11):2355–2392; doi: 10.1017/S0144686X19000527.
255 256 257	9.	Steinsheim G, Malmedal W, Follestad T, et al. Factors associated with subjective burden among informal caregivers of home-dwelling people with dementia: a cross-sectional study. BMC Geriatrics 2023;23(1):644; doi: 10.1186/s12877-023-04358-3.
258 259 260	10.	Bernstein A, Harrison KL, Dulaney S, et al. The Role of Care Navigators Working with People with Dementia and their Caregivers. J Alzheimers Dis 2019;71(1):45–55; doi: 10.3233/JAD-180957.
261 262 263 264	11.	Possin KL, Merrilees JJ, Dulaney S, et al. Effect of Collaborative Dementia Care via Telephone and Internet on Quality of Life, Caregiver Well-being, and Health Care Use: The Care Ecosystem Randomized Clinical Trial. JAMA Intern Med 2019;179(12):1658–1667; doi: 10.1001/jamainternmed.2019.4101.
265 266 267	12.	Kallmyer BA, Bass D, Baumgart M, et al. Dementia care navigation: Building toward a common definition, key principles, and outcomes. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2023;9(3):e12408; doi: 10.1002/trc2.12408.
268 269 270	13.	Hirschman KB, McHugh M, Morgan B. An integrative review of measures of transitions and care coordination for persons living with dementia and their caregivers. Alzheimers Dement (N Y) 2023;9(3):e12391; doi: 10.1002/trc2.12391.

- 14. Gallagher VT, Reilly SE, Worthington G, et al. Individualized Coordination and
   Empowerment for Care Partners of Persons with Dementia (ICECaP): Study rationale and
   protocol. Contemp Clin Trials 2024;137:107418; doi: 10.1016/j.cct.2023.107418.
- 15. Katz S, Ford AB, Moskowitz RW, et al. STUDIES OF ILLNESS IN THE AGED. THE INDEX
  OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL
  FUNCTION. JAMA 1963;185:914–919; doi: 10.1001/jama.1963.03060120024016.
- 16. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental
   activities of daily living. Gerontologist 1969;9(3):179–186.
- 17. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a Brief Clinical Form of
   the Neuropsychiatric Inventory. JNP 2000;12(2):233–239; doi: 10.1176/jnp.12.2.233.
- 18. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 2019;95:103208; doi: 10.1016/j.jbi.2019.103208.
- 19. Bédard M, Molloy DW, Squire L, et al. The Zarit Burden Interview: a new short version and screening version. Gerontologist 2001;41(5):652–657; doi: 10.1093/geront/41.5.652.
- 286 20. Eaton WW, Smith C, Ybarra M, et al. Center for Epidemiologic Studies Depression Scale:
  287 Review and Revision (CESD and CESD-R). In: The Use of Psychological Testing for
  288 Treatment Planning and Outcomes Assessment: Instruments for Adults, Volume 3, 3rd Ed
  289 Lawrence Erlbaum Associates Publishers: Mahwah, NJ, US; 2004; pp. 363–377.
- 290 21. Johnco C, Knight A, Tadic D, et al. Psychometric properties of the Geriatric Anxiety
   291 Inventory (GAI) and its short-form (GAI-SF) in a clinical and non-clinical sample of older
   292 adults. Int Psychogeriatr 2015;27(7):1089–1097; doi: 10.1017/S1041610214001586.
- 293 22. Teri L, Truax P, Logsdon R, et al. Assessment of behavioral problems in dementia: the
   294 revised memory and behavior problems checklist. Psychol Aging 1992;7(4):622–631; doi:
   295 10.1037//0882-7974.7.4.622.
- 23. Topp CW, Østergaard SD, Søndergaard S, et al. The WHO-5 Well-Being Index: a
  systematic review of the literature. Psychother Psychosom 2015;84(3):167–176; doi:
  10.1159/000376585.
- 299

### 301 Figure 1. Sample Consort Flow Diagram.

#### **CONSORT 2010 Flow Diagram**

